

IMPACT FACTOR Pu



an Open Access Journal by MDPI

# **Gene Therapy**

Guest Editor:

### Dr. Kenneth Lundstrom

PanTherapeutics, Rue des Remparts 4, CH-1095 Lutry, Switzerland

Deadline for manuscript submissions:

closed (31 August 2018)

## Message from the Guest Editor

Dear Colleagues,

It is my great pleasure to introduce the Special Issue on "Gene Therapy". In the 1990s, gene therapy was considered most promising and the perfect technology to develop medicines of the future. Today, an increasing number of clinical trials are in progress and several gene therapy-based drugs have been approved. It is therefore most appropriate to share the latest development with the scientific community in this special issue. As you will notice, the articles cover engineering of non-viral and viral vectors, gene therapy applications for various indications, such as cancer, hemophilia, AIDS, severe combined immunodeficiency and neurological diseases. Moreover immunotherapy, which has received a lot of attention recently, is presented in detail.

Dr. Kenneth Lundstrom *Guest Editor* 









an Open Access Journal by MDPI

### **Editor-in-Chief**

#### Prof. Dr. Maurizio Battino

Department of Odontostomatologic and Specialized Clinical Sciences, Sez-Biochimica, Faculty of Medicine, Università Politecnica delle Marche, Via Ranieri 65, 60100 Ancona, Italy

# Message from the Editor-in-Chief

*Diseases* is an international, peer-reviewed, open access, multidisciplinary journal that focuses on the latest outstanding research concerning diseases and conditions. Research articles, reviews, and other contents are released on the Internet immediately after acceptance. This journal aims to cover international conferences and symposia as new targets.

*Diseases* is increasingly gaining acceptance and visibility within scholars, and after only a few years of life, Diseases is now also covering specific topics with dedicated special issues. We would be pleased to welcome you as one of our authors

### **Author Benefits**

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High visibility:** indexed within Scopus, ESCI (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

**Rapid Publication:** manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.8 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the second half of 2023).

#### **Contact Us**